6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | -$109M | 0.0% | -1130.6% | -$94M | $50M | $320M |
| 2024 | $8M | -$89M | 0.0% | -1097.6% | -$82M | $44M | $139M |
| 2023 | $15M | -$112M | 0.0% | -468.8% | -$77M | $41M | $144M |
| 2022 | $3M | -$166M | 0.0% | -6492.7% | -$109M | $38M | $88M |
| 2021 | — | -$175M | — | — | -$132M | $37M | $149M |
| 2020 | — | -$60M | — | — | -$31M | — | $251M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$42M | — | — | -$41M | $49M | $277M |
| Dec '25 | $5M | -$28M | 0.0% | -516.0% | -$27M | $50M | $320M |
| Sep '25 | $0 | -$33M | — | — | -$24M | $51M | $297M |
| Jun '25 | $2M | -$27M | 0.0% | -1347.1% | — | $41M | $313M |
| Mar '25 | $2M | -$22M | 0.0% | -930.5% | -$22M | $42M | $117M |
| Dec '24 | $2M | -$19M | 0.0% | -985.8% | -$18M | $44M | $139M |
| Sep '24 | $2M | -$26M | 0.0% | -1448.4% | -$22M | $43M | $158M |
| Jun '24 | $1M | -$21M | 0.0% | -1915.4% | -$22M | $38M | $173M |
| Mar '24 | $3M | -$24M | 0.0% | -713.3% | -$20M | $41M | $124M |
| Dec '23 | $4M | $48M | 0.0% | -450.8% | -$16M | $41M | $144M |
| Sep '23 | $5M | -$117M | 0.0% | -342.4% | -$18M | $39M | $164M |
| Jun '23 | $2M | -$25M | 0.0% | -976.4% | -$19M | $38M | $45M |
| Mar '23 | $5M | -$18M | 0.0% | -351.9% | -$24M | $38M | $63M |
| Dec '22 | — | -$55M | — | — | $12M | $38M | $88M |
| Sep '22 | — | -$27M | — | — | -$31M | $38M | $34M |
| Jun '22 | — | -$34M | — | — | -$41M | $38M | $66M |
| Mar '22 | — | -$50M | — | — | -$49M | $37M | $97M |
| Dec '21 | — | -$50M | — | — | -$49M | $37M | $149M |
| Sep '21 | — | -$51M | — | — | -$35M | $28M | $189M |
| Jun '21 | — | -$41M | — | — | -$26M | — | $197M |
How the market has priced TSHA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Taysha Gene Therapies, Inc.'s revenue has grown 57.5% per year. These are computed facts, not advice.
As of FY2025, Taysha Gene Therapies, Inc. reported $50M of total debt against $320M of cash; operating income covered interest expense -1753.9×.
In FY2025, gross margin was —, operating margin -1130.6%, and net margin -1115.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.